XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.1
Collaboration and License Agreements - Additional Information (Details) - USD ($)
 3 Months Ended
Apr. 09, 2021
Jan. 06, 2021
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Aug. 31, 2021
Collaboration and License Agreements [Line items]            
Common stock, shares issued     62,585,043   61,712,577  
Proceeds from offering of common stock, net of issuance costs     $ 1,627,000      
Revenue     3,317,000 $ 16,349,000    
Deferred revenue     19,686,000   $ 21,244,000  
Prepaid expenses     17,060,000   17,434,000  
Research and development     19,972,000 25,593,000    
Revenue recorded included in deferred revenue     3,300,000      
Servier | Program Purchase Agreement            
Collaboration and License Agreements [Line items]            
Research and development $ 1,250,000          
Waiver of milestone payment $ 18,750,000          
Development and License Agreement | Eli Lilly and Company            
Collaboration and License Agreements [Line items]            
Upfront cash payment   $ 100,000,000.0        
Milestone payments to be received for additional targets   420,000,000.0        
Transaction price from the Stock Purchase Agreement   $ 7,300,000        
Revenue     3,300,000 5,400,000    
Deferred revenue related to agreement     85,400,000   88,300,000  
Development and License Agreement | Eli Lilly and Company | Current Liabilities            
Collaboration and License Agreements [Line items]            
Deferred revenue     19,700,000   21,200,000  
Development and License Agreement | Eli Lilly and Company | Stock Purchase Agreement            
Collaboration and License Agreements [Line items]            
Common stock, shares issued   3,762,190        
Proceeds from offering of common stock, net of issuance costs   $ 35,000,000.0        
Upfront Compensation   135,000,000.0        
Equity upon the issuance of the shares   27,700,000        
Transaction price allocated to the revenue arrangement   $ 107,300,000        
Development and License Agreement | iECURE            
Collaboration and License Agreements [Line items]            
Investment in equity securities     0     $ 500,000
Prepaid Expense and Other Assets     12,200,000     17,400,000
Prepaid expenses     9,800,000     15,100,000
Other Assets     2,400,000     $ 2,300,000
Research and development     700,000      
Development And Commercial License Agreement | Servier            
Collaboration and License Agreements [Line items]            
Deferred revenue related to agreement     0   $ 0  
Revenue recorded included in deferred revenue     $ 0 $ 10,300,000